Abstract: The present invention is directed to methods and agents for modulating adipogenesis. More particularly, the present invention relates to molecules that modulate the level or functional activity of inosine-5? monophosphate dehydrogenase (IMPDH) and to their use in modulating the accumulation of lipids in adipocytes and/or the differentiation of preadipocytes to adipocytes for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
Abstract: The present invention is directed to novel substituted aminocyclohexanes which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
Type:
Grant
Filed:
May 19, 2006
Date of Patent:
March 15, 2011
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Tesfaye Biftu, Danqing Feng, Xiaoxia Qian, Ann E. Weber, Jason Cox
Abstract: Compositions based on amino acids are described, in particular for oral or parenteral use, suitable for treating heart insufficiency. The compositions according to the invention comprise up to 75% of the branched chain amino acids leucine, isoleucine and valine, as active ingredients. Preferably, the compositions also comprise, as further active ingredients, up to 50% of threonine and lysine. Other essential amino acids are preferably also provided (in particular methionine, phenylalanine, histidine, triphtophan) as well as non essential amino acids (in particular tyrosine and/or cyst(e)ine—i.e. cystine and cyst(e)ine). Other amino acids can be added, provided that their sum is in a percentage being lower than 20% with respect to the other active ingredients, and less than 10% for each single amino acid.
Abstract: The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying ?-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of the expression of the MAPK9 gene or gene product. In one embodiment, the present invention contemplates the diagnosis, identification, production, and use of compounds which modulate MAPK9 gene expression or the activity of the MAPK9 gene product including but not limited to, JNK2, the nucleic acid encoding MAPK9 and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules. The present invention contemplates a variety of pharmaceutical formulations and routes of administration for such compounds.
Type:
Grant
Filed:
December 21, 2006
Date of Patent:
March 1, 2011
Assignee:
University Of Massachusetts Medical School
Abstract: The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.
Abstract: The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and/or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of diabetes in an at-risk patient and/or treat or prevent the onset of diabetes-associated complications.
Type:
Grant
Filed:
November 5, 2008
Date of Patent:
February 22, 2011
Assignee:
Omega Bio-Pharma (I.P.3) Limited
Inventors:
Bill Piu Chan, Gary Kwan Po Wong, Jinxian Xu, Francis Chi
Abstract: The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention also relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion. The methods of the present invention comprise administration of a selective ?-receptor antagonist, such as guanidinylated naltrindole (GNTI), or pharmaceutically acceptable derivatives thereof to a subject in need thereof.
Abstract: A liquid seasoning, comprising: (A) 3.55% by weight or less of sodium; (B) 0.5 to 4.2% by weight of potassium; and (C) 0.05 to 20% by weight of a substance having an antihypertensive effect. Salty taste is sufficiently provided despite its low sodium concentration, and pharmacological functions such as an antihypertensive effect are also provided at a high level.
Type:
Grant
Filed:
May 19, 2006
Date of Patent:
February 15, 2011
Assignee:
Kao Corporation
Inventors:
Shigemi Tsuchiya, Yoko Seo, Jun Kohori, Ryuji Ochiai, Atsushi Suzuki
Abstract: The present application is directed to a method of treating diseases of the central nervous system (CNS) comprising administering to a individual in need of treatment a therapeutically effective amount of an inhibitor of histone deacetylase. In particular embodiments, the CNS disease is a neurodegenerative disease. In further embodiments, the neurogenerative disease is an inherited neurodegenerative disease, such as those inherited neurodegenerative diseases which are polyglutamine expansion diseases. The individual can be a mammal such as a primate or human.
Type:
Grant
Filed:
November 18, 2005
Date of Patent:
February 1, 2011
Assignee:
Sloan-Kettering Institute for Cancer Research
Inventors:
Victoria M. Richon, Paul A. Marks, Richard A. Rifkind
Abstract: The present application features the use of the somatostatin subtype 3 receptor (SST3) as a target for affecting insulin secretion and for diagnosing diabetes related disorders. Glucose stimulated insulin secretion was found to be stimulated by knocking down expression of SST3 and through the use of a SST3 selective antagonist.
Type:
Grant
Filed:
November 17, 2006
Date of Patent:
February 1, 2011
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Yun-Ping Zhou, Jing Li, Weizhen Wu, Jin Shang, John R. Thompson, Nancy A. Thornberry
Abstract: Disclosed are compositions, including low-calorie beverages or liquids, comprising isoleucine, leucine, valine, cysteine, and methionine, in specified amounts, weight ratios, or both. The compositions are especially useful in treating individuals afflicted with impaired glucose tolerance or diabetes.
Type:
Grant
Filed:
March 21, 2006
Date of Patent:
February 1, 2011
Assignee:
Abbott Laboratories
Inventors:
Neile Edens, Marti S. Bergana, Kati Shearer, Terrence B. Mazer, Joseph E. Walton, David R. Wolf
Abstract: The present invention provides a method of treating diseases or disorders benefiting from inactivating or down regulating the activity of the capsaicin receptor in a mammal by inhibiting the activity of the capsaicin receptor. The present invention also provides a method of treating obesity and obesity-related diseases and disorders in a mammal by inhibiting the activity of the capasaicin receptor.
Abstract: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.
Type:
Grant
Filed:
March 22, 2004
Date of Patent:
January 25, 2011
Assignee:
Cordis Corporation
Inventors:
Robert Falotico, Tom Jay Parry, Jonathon Z. Zhao
Abstract: The invention relates to the use of a c-Abl-, PDGF-R-, or c-kit- tyrosine kinase inhibitor, e.g. 4-(4-methylpiperazin-1 -ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of diabetes, e.g. type I diabetes, type II diabetes.
Type:
Grant
Filed:
May 26, 2004
Date of Patent:
January 25, 2011
Inventors:
Robert Per Hägerkvist, Nils Richard Welsh
Abstract: It is intended to find a compound that is structurally simpler than yohimbine, a pentacyclic condensed heterocyclic compound, and has an effect similar to that of yohimbine. The present invention relates to a pharmaceutical or food composition for ?2 receptor blockage comprising a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: (wherein R1 represents a hydrogen, alkyl group, alkenyl group, alkynyl group, aromatic group, aralkyl group, acyl group, arylsulfonyl group, alkylsulfonyl group, or hydroxyl group; R2 represents a hydrocarbon group; R3, R4, R5, R6, and R7 are the same or different and represent a hydrogen, halogen, alkyl group, or alkoxy group; R8 represents a hydrogen or acyl group; n represents an integer of 1 to 6; and a and b are the same or different and represent 1 or 0).
Type:
Grant
Filed:
September 16, 2005
Date of Patent:
January 18, 2011
Inventors:
Masanori Somei, Koki Shigenobu, Yoshio Tanaka
Abstract: The present invention relates to a recognition that an analog of ?KG can increase glucose-induced insulin secretion in vitro and in vivo in animals, particularly in mammals, and more particularly in humans and in rodents. By employing the methods of the invention, insulin secretion can be increased.
Type:
Grant
Filed:
August 20, 2004
Date of Patent:
January 4, 2011
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Alan D. Attie, Mary E. Rabaglia, Ronald T. Raines, Mark Gray-Keller
Abstract: Self-heating, post-foaming shave gels and shave gel products are provided. In some implementations, the shave gels include a non-ionic emulsifier system, e.g., including one or more fatty alcohol ethoxylates.
Type:
Grant
Filed:
November 25, 2003
Date of Patent:
December 21, 2010
Assignee:
The Gillette Company
Inventors:
Gurusamy Manivannan, Alexander Novikov, Stephen Thong, Alfred Barnet, Yun Xu, Ronald McLaughlin
Abstract: The compound represented by the general formula (I) is administered to a subject suffering from diabetes or obesity. In the formula (I), R1 and R2 independently represent an aliphatic hydrocarbon group having 1 to 10 carbon atoms or phenyl group, and arbitrary hydrogen atoms on the aliphatic hydrocarbon group and the phenyl group may be replaced by halogen, X1 represents halogen, and X2 represents hydrogen or halogen.
Type:
Grant
Filed:
October 24, 2007
Date of Patent:
December 7, 2010
Assignee:
National University Corporation Gunma University
Abstract: A method of treating hyperinsulinemia. The method includes administering a therapeutically effective amount of a compound selected from the group consisting of catalpic acid, glyceride esters thereof, pharmaceutically-suitable salts thereof, and combinations thereof. The compound may be administered orally or parenterally.
Abstract: Compounds of Formula I are described along with pharmaceutical formulations thereof, and methods of treating disorders such as diabetes and neurodegenerative diseases with such compounds.